Trial reportDrug design, development and therapy2023
Determination of the 50% and 95% Effective Dose of Remimazolam Combined with Propofol for Intravenous Sedation During Day-Surgery Hysteroscopy.
Trial report in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05990673 (Determination of the 50% and 95% Effective Dose of Remimazolam for Intravenous Anesthesia Induction in Pediatric Patients), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determination of the 50% and 95% Effective Dose of Remimazolam for Intravenous Anesthesia Induction in Pediatric Patients
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- EDFrontiers in medicine · 2026Trial
- The effect of remimazolam combined with low-dose propofol on diaphragmatic function in patients undergoing hysteroscopic surgery: a randomized clinical trial.BMC anesthesiology · 2025Trial
- Effect of Fentanyl on Remimazolam-Induced Sedation in Female Patients Undergoing Hysteroscopic Surgery: A Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- Effects of Remimazolam-Propofol with Flumazenil Reversal on the Emergence Time and Hemodynamics of Patients Undergoing Laparoscopic Partial Hepatectomy: A Prospective Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- Effect of different doses of esketamine on the median effective concentration of propofol for inhibiting body movement during hysteroscopy.Scientific reports · 2024Trial
- Comparison of hypotension between propofol and remimazolam-propofol combinations sedation for day-surgery hysteroscopy: a prospective, randomized, controlled trial.BMC anesthesiology · 2024Trial
- Effect of converting from propofol to remimazolam with flumazenil reversal on recovery from anesthesia in outpatients with mental disabilities: a randomized controlled trial.BMC anesthesiology · 2024Trial
- Comparison of Remimazolam and Propofol for Intravenous Anesthesia on Trigeminocardiac Reflex in Percutaneous Balloon Compression for Trigeminal Neuralgia: A Randomized Controlled Trial.Drug design, development and therapy · 2024Trial
- The Effects of Low-Dose Remimazolam Adjunct on Propofol-Remifentanil Anaesthesia in Day Case Gynaecological Surgery: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Effective Doses of Oliceridine Combined with Propofol for Painless Hysteroscopy: A Prospective Dose-Finding Study.International journal of general medicine · 2025Article
- Effects of different doses of alfentanil combined with target-controlled infusion (TCI) of propofol for daytime hysteroscopy.Heliyon · 2024Article
- Modified Dixon sequential method to determine the effective dose of alfentanil compounded with propofol for day-case hysteroscopy.Therapeutic advances in drug safety · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Remimazolam has demonstrated the potential as a valuable medication for procedural sedation. However, there were some shortcomings for higher doses of remimazolam during hysteroscopy in spite of less frequent adverse events. The aim of this study was to find the 50% and 95% effective dose (ED Patients and Methods: Patients were randomly assigned evenly (20 per group) to one of five different dosage of remimazolam: group A (0.05mg/kg), group B (0.075mg/kg), group C (0.1mg/kg), group D (0.125mg/kg) or group E (0.15mg/kg). Intravenous injection of sufentanil 0.1µg/kg was administered before sedative medication. Intravenous anesthesia was commenced with remimazolam. Subsequently, propofol was administered at 1mg/kg and maintained at 6mg/kg/h. Success was defined when the patient did not move during cervical dilation, had sufficient sedation as judged by SE <60 and no requirement for rescue doses. The success rate, induce and average dosage of propofol, the induction time, total surgery time, recovery time, and adverse events were recorded. Estimate of ED Results: The mean (95% CI) values for ED Conclusion: The dose-response effects of remimazolam were evaluated for intravenous sedation during hysteroscopy. A combination of remimazolam and propofol was recommended to produce stabler sedation, reduce the total dosage and have less effect on cardiovascular and respiratory depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.